Enjoy complimentary customisation on priority with our Enterprise License!
The anticoagulant reversal drugs market share is expected to increase by USD 877.37 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 12.27%.
This anticoagulant reversal drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers anticoagulant reversal drugs market segmentation by distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy) and geography (North America, Europe, Asia, and Rest of World (ROW)). The anticoagulant reversal drugs market report also offers information on several market vendors, including Amboss GmbH, Amneal Pharmaceuticals Inc., AstraZeneca Plc, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Covis Pharma BV, CSL Ltd., GoodRx Holdings Inc., Midas Pharma GmbH, and Pfizer Inc. among others.
Download the Free Report Sample to Unlock the Anticoagulant Reversal Drugs Market Size for the Forecast Period and Other Important Statistics
The increasing prevalence of coagulation disorders is notably driving the anticoagulant reversal drugs market growth, although factors such as product recalls may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the anticoagulant reversal drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Anticoagulant Reversal Drugs Market Driver
One of the key factors driving the global anticoagulant reversal drugs market growth is the increasing prevalence of coagulation disorders, such as Von Willebrand disease, hemophilia, deep venous thrombosis, hypercoagulable states, and clotting factor deficiencies. For instance, according to the data published by the CDC in July 2020, nearly 400 babies are born with hemophilia A every year in the US. In addition, according to the data stated by the CDC in February 2020, nearly 900,000 people in the US are affected by venous thromboembolism, also known as DVT/PE, every year. Furthermore, coagulation tests are recommended by physicians during major surgeries. Such factors will boost the demand for anticoagulant reversal drugs and result in market growth during the forecast period.
Key Anticoagulant Reversal Drugs Market Trend
Recent developments is one of the key anticoagulant reversal drugs market trends that is expected to impact the industry positively in the forecast period. Janssen Research and Development LLC started a Phase 1 clinical trial in July 2020 to see if 4-Factor Prothrombin Complex Concentrate (4F-PCC) and Recombinant Human Factor VIIa could reverse the anticoagulant effect of the medication JNJ-70033093. Similarly, in July 2020, Portola Pharmaceuticals Inc. stated that the Centers for Medicare & Medicaid Services (CMS) had established a permanent J-code (J7169) for Andexxa, a recombinant coagulation factor Xa, allowing coverage in hospital outpatient settings. Such developments will provide a platform for sustainable innovation, growth, and value creation for the market, which will further support the market in the coming years.
Key Anticoagulant Reversal Drugs Market Challenge
One of the key challenges to the global anticoagulant reversal drugs market growth is product recalls. For instance, in June 2019, potency concerns provoked B. Braun Medical Inc. to recall 40,176 bags of heparin sodium in dextrose. The recall affected heparin sodium of 25,000 USP units per 250 ml in 5% dextrose injection. Similarly, in April 2020, as per FDA, SCA Pharmaceuticals recalled ten lots or bags of compounded heparin sodium, an anticoagulant packaged in 500 ml or 1000 ml intravenous bags. The packs contained benzyl alcohol, an unlabeled preservative that can cause serious side effects in preterm and low-birth-weight babies. Such factors are expected to challenge the growth of the market in focus during the forecast period.
This anticoagulant reversal drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global anticoagulant reversal drugs market as a part of the pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the anticoagulant reversal drugs market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the anticoagulant reversal drugs market encompasses successful business strategies deployed by the key vendors. The anticoagulant reversal drugs market is fragmented and the vendors are deploying growth strategies such as investments in research and development to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The anticoagulant reversal drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the anticoagulant reversal drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request for a FREE sample now!
43% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for anticoagulant reversal drugs in North America. Market growth in this region will be faster than the growth of the market in other regions.
The availability of direct reimbursement policies and modern healthcare infrastructure will facilitate the anticoagulant reversal drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
Because of the emerging link between COVID-19 infection and blood diseases, the impact of the pandemic on the studied market is projected to be significant in the region. According to a study published in the American Journal of Hematology in 2020 by the Harvard Medical School, COVID-19 infected patients who were admitted with severe related complications had high levels of the blood-clotting protein Factor V, which could eventually lead to the formation of blood clots in various organs. Moreover, numerous important companies in the analyzed market have a presence in the US and are projected to expand their market presence through R and D and product approvals. As a result of the aforementioned factors, the anticoagulant reversal medicines market in North America is expected to increase significantly over the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The anticoagulant reversal drugs market share growth by the hospital pharmacy segment will be significant during the forecast period. This growth is attributed to the rise in the number of hospitalization of people for serious cases to basic monitoring during surgeries, which leads hospitals to increase their investments in hospital pharmacies.
This report provides an accurate prediction of the contribution of all the segments to the growth of the anticoagulant reversal drugs market size and actionable market insights on post COVID-19 impact on each segment.
Anticoagulants market - The market size has the potential to grow by USD 13.61 billion during 2020-2024, and the market's growth momentum will accelerate during the forecast period.
Anticoccidial Drugs market - The market share is expected to increase to USD 76.95 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 4.1%.
Anticoagulant Reversal Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 12.27% |
Market growth 2022-2026 |
$ 877.37 million |
Market structure |
Fragmented |
YoY growth (%) |
12.0 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 43% |
Key consumer countries |
US, Canada, UK, Germany, France, and China |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Amboss GmbH, Amneal Pharmaceuticals Inc., AstraZeneca Plc, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Covis Pharma BV, CSL Ltd., GoodRx Holdings Inc., Midas Pharma GmbH, and Pfizer Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Distribution Channel
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.